Skip to content

Study · Not a test of the peptide alone · 2024

4 results

Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.

Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R

Nutrition, metabolism, and cardiovascular diseases : NMCD23 Mar 2024Cited by 4 (Europe PMC)

PMID38693036 (opens in a new tab)DOI10.1016/j.numecd.2024.03.023 (opens in a new tab)PepBankPUB-38693036
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes on a GLP-1 RA, adding glargine 300 to the ongoing GLP-1 RA improved fasting blood glucose more than switching to iDegLira (degludec plus liraglutide).

    In plain wordsIn adults with type 2 diabetes, adding basal insulin to an ongoing GLP-1 drug lowered fasting glucose more than switching to a fixed insulin-liraglutide product.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting blood glucose after 6 months
    Study

    n = 515

    Comparator
    iDegLira (fixed combination)
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    FBG mean difference
    −24.05 mg/dl
    free vs fixed combination

    Source sentences

    Summary
    statistically significant greater FBG improvement [estimated mean difference and 95% confidence intervals: -24.05 mg/dl (-37.04; -11.06; p = 0.0003)
    1 context sentence
    Summary · context
    A retrospective comparative effectiveness analysis of the add-on of glargine 300 U/mL (Gla-300) to ongoing GLP-1 RA vs. switch to fixed ratio combination of degludec and liraglutide (iDegLira) was performed.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneObservational studyOther

    In adults with type 2 diabetes on a GLP-1 RA, the basal insulin dose rose more with glargine 300 added to the GLP-1 RA than with iDegLira.

    In plain wordsIn adults with type 2 diabetes, the insulin dose rose more with insulin added to a GLP-1 drug than with a fixed insulin-liraglutide product.

    Peptide
    Liraglutide
    Outcome
    IncreaseBasal insulin dose increase after 6 months
    Study

    n = 515

    Comparator
    iDegLira (fixed combination)
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    BI dose difference
    0.03 U/kg
    free vs fixed combination

    Source sentences

    Summary
    BI dose increase [+0.03 U/kg (95%CI 0.00; 0.06); p = 0.009
    1 context sentence
    Summary · context
    A retrospective comparative effectiveness analysis of the add-on of glargine 300 U/mL (Gla-300) to ongoing GLP-1 RA vs. switch to fixed ratio combination of degludec and liraglutide (iDegLira) was performed.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, HbA1c reductions were larger with glargine 300 plus a GLP-1 RA than with iDegLira only as a trend, without statistical significance.

    In plain wordsIn adults with type 2 diabetes, HbA1c fell somewhat more with insulin added to a GLP-1 drug than with a fixed product, but not significantly.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c reduction after 6 months
    Study

    n = 515

    Comparator
    iDegLira (fixed combination)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Trends of larger HbA1c and body weight reductions with the free combination were also found, without reaching the statistical significance.
    1 context sentence
    Summary · context
    A retrospective comparative effectiveness analysis of the add-on of glargine 300 U/mL (Gla-300) to ongoing GLP-1 RA vs. switch to fixed ratio combination of degludec and liraglutide (iDegLira) was performed.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, body weight reductions were larger with glargine 300 plus a GLP-1 RA than with iDegLira only as a trend, without statistical significance.

    In plain wordsIn adults with type 2 diabetes, weight fell somewhat more with insulin added to a GLP-1 drug than with a fixed product, but not significantly.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight reduction after 6 months
    Study

    n = 515

    Comparator
    iDegLira (fixed combination)
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Trends of larger HbA1c and body weight reductions with the free combination were also found, without reaching the statistical significance.
    1 context sentence
    Summary · context
    A retrospective comparative effectiveness analysis of the add-on of glargine 300 U/mL (Gla-300) to ongoing GLP-1 RA vs. switch to fixed ratio combination of degludec and liraglutide (iDegLira) was performed.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.